Clinical Trial: Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy of Relapsed/Refractory B-Cell Lymphoma

U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT07546630) titled 'Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy of Relapsed/Refractory B-Cell Lymphoma' on April 16.

Brief Summary: This is a single arm study to evaluate the safety and efficacy of Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell therapy for Relapsed/Refractory B-Cell Lymphoma

Study Start Date: April 30

Study Type: INTERVENTIONAL

Condition: Relapsed/Refractory B-Cell Lymphoma

Intervention: GENETIC: CD19/CD20 Tandem Dual CAR-T

Each subject will be infused with single dose of CD19/CD20 Tandem Dual CAR-T. A classic "3+3" dose escalation will be employed. The low dose is 2x10^6 / kg, the medium dose is 4x10^6 /kg, and th...